DOCSLIB.ORG

Good Morning Vietnam

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Good Morning Vietnam March 24, 2021 Good Morning Vietnam To subscribe to our report, please contact us at [email protected] Market performance VIETNAM STOCK MARKET Last trade 1D (%) 1M (%) 1Y (%) VN-INDEX 1,183.45 -0.92 1.85 79.53 Banks fell, market plunged HNX 272.34 -0.91 14.48 180.91 Vietnam stock market decreased significantly as most of major stocks went down. VN-Index UPCOM 81.14 -0.16 6.46 67.27 dropped right at the start combined with increasing volume that the loss widened during MSCI EM 1,323.77 -0.94 -3.85 65.13 the morning without any recovery signal. In the afternoon, the index moved sideways and NIKKEI 28,783.46 -0.73 -2.99 59.09 could not recover as overload problem hindered buying forces. At last, the index closed at HANG SENG 28,497.38 -1.34 -4.11 25.74 1,183.45 points, lost 10.98 points (equivalent to -0.92% DoD). As usual, the trading volume KOSPI 2,989.27 -0.51 -0.19 85.67 and value maintained at high level of 683.7mn shares and VND15,415bn, respectively. FTSE 6,699.19 -0.40 0.60 23.01 Banking and Real Estate stocks decline was the major pressure of the market: VCB (-1.24%), S&P 500 3,910.52 -0.76 -0.38 59.79 BID (-2.13%), TCB (-2.06%), VIC (-0.75%), CTG (-1.46%), VHM (-0.60%). NASDAQ 13,227.70 -1.12 -2.72 78.32 Overseas investors recorded a net-selling worth of VND288.24bn on HOSE which marked Valuation their 1-month consecutive selling. Therein, they sold VNM (VND187.4bn), CTG P/E (x) P/B (x) ROE (%) (VND76.6bn), VCB (VND31.8bn), VIC (VND29.8bn), PLX (VND28bn), YEG (VND24.7bn), etc. VN-INDEX 18.24 2.48 13.69 By contrast, MSB (VND107.4bn), MBB (VND91.1bn), ACB (VND11.5bn) saw net inflows. SET INDEX 39.38 1.71 4.34 JCI INDEX 33.26 1.61 4.12 Market highlight: Investors add to top Emerging-Market ETFs in PCOMP INDEX 28.94 1.58 6.15 US$34bn streak Investors added money to the largest exchange-traded funds dedicated to emerging Key rates markets last week, extending a 20-week inflow to the asset class as investors look past the Last trade 1D (bps) 1M (bps) 1Y (bps) Policy rate 4.00 0 0 -100 rise in U.S. Treasury yields. The market’s top two developing-nation ETFs were the main 5-year 1.10 -1 5 -109 beneficiaries of a US$2.07bn inflow to the asset class in the week ended 19 March, 10-year 2.42 -2 15 -68 suggesting broad appetite for risk. BlackRock’s US$78.7bn iShares Core MSCI Emerging Markets ETF, or IEMG, and the US$78.3bn Vanguard FTSE Emerging Markets ETF, known as FX VWO, attracted US$973mn and US$411mn, respectively. Inflows to emerging markets have Last trade 1D (%) 1M (%) 1Y (%) totaled US$34.4bn in the past 20 weeks -- of which US$17.5bn were added this year. That US$/VND 23,069 0.00 -0.19 2.09 was the longest sequence of weekly inflows in two years and comes despite the U.S. bond US$/KRW 1,134 -0.42 -1.97 10.16 market rout that has been weighing on risk assets. No country suffered significant outflows. US$/JPY 109 -0.04 -2.54 2.39 China and Hong Kong were again the places that received the most money, due to their US$/EUR 0.84 0.06 2.76 -8.91 weighting in the top emerging-market funds as well as inflows to some of the main ETFs US$/GBP 0.73 0.14 2.97 -14.36 dedicated to Chinese stocks, including the US$6.7bn iShares MSCI China ETF. Bonds also US$/SGD 1.35 -0.15 -1.98 7.43 received new cash, led by the US$17.2bn iShares JP Morgan USD Emerging Markets Bond Daily trading value (turnover) ETF, or EMB, which posted a US$381mn inflow, the second in a row. Today (US$mn) 1M Avg (mn) 1Y Avg (mn) Chau Bui, +84 28 3910 2222, [email protected] VN-INDEX 604 597 326 VN-Index valuation: 10-year band chart HNX 112 97 40 UPCOM 45 48 20 (x) P/E -2SD -1SD AVG +1SD +2SD 22 Daily foreign trading value 20 Buy Sell Net (US$mn) VN-INDEX 41.00 55.68 -14.68 18 HNX 0.8 0.4 0.4 16 UPCOM 1.6 1.0 0.6 14 12 Institutional client contacts Head of Wholesale and Korean Clients 10 Mr. Ahn Jong Hoon [email protected] 8 6 Head of Institutional (ex Korea) Mar 11 Mar 13 Mar 15 Mar 17 Mar 19 Mar 21 Mr. Steven Derek Brown [email protected] Source: Bloomberg, Mirae Asset Research See the last page of this report for important disclosures March 24, 2021 Good Morning Vietnam Short news Airlines forecast to lose over VND15tr in 2021 Vietnamese airlines are projected to post a total loss of VND15tr (US$650mn) in 2021, with their revenue continuing to plunge compared to that of last year, according to the Vietnam Aviation Business Association (VABA). The aviation sector has so far borne the brunt of three waves of COVID-19 outbreaks, which has frozen international travel. In 2M21, their international passenger throughput amounted to 66,600, down 98.8% YoY. These figures were mentioned in the VABA’s proposal for credit assistance to aviation companies, which was recently submitted to the Ministry of Planning and Investment. Vietnam may produce own COVID-19 vaccines in third quarter Vietnam expects to start producing its own COVID-19 vaccine by the end of the third quarter, according to the Ministry of Health. Currently, four Vietnamese vaccines are in development, produced by Nanogen Pharmaceutical Biotechnology JSC, the Institute of Vaccines and Medical Biologicals (IVAC), Vaccine and Biological Production Company No. 1 (Vabiotech) and the Center for Research and Production of Vaccines and Biologicals (Polyvac). Nanocovax by Nanogen entered its second phase of human trials in February 2021, while Covivac began its first phase earlier this month. Nguyen Ngo Quang, deputy head of the Administration of Science, Technology and Training under the health ministry, said the vaccine development process has been hastened while still abiding by stringent procedures. GMD: Vietnam's largest deep seaport Gemalink to reach 80% capacity in 2021 Gemalink Port, Vietnam's largest deep seaport, will put into use at least 80% of its designed capacity this year and reach its full capacity of 1.5mn TEU by 2022. These plans were shared during Vietnam Prime Minister Nguyen Xuan Phuc's inspection trip to Gemalink Port in the southern province of Ba Ria-Vung Tau. Beginning construction in February 2019, Gemalink is the biggest seaport in the Cai Mep-Thi Vai complex and one of the world’s 19 largest deep seaports with the capability to receive the world's largest ships (up to 200,000 DWT) today. Gemalink has a total investment capital of US$520mn with the first phase of US$330mn and the second phase of US$190mn. VIC VN: Vingroup Plans to Offer as Much as $500M of Overseas Bonds Vingroup JSC (VIC VN/TRADING BUY/TP: VND119,500/CP: VND106,500) plans to sell as much as US$500m of 5-year bonds in U.S. dollars in international markets in 2021 that interest rate may be fixed or floating or mix of both. Buyers can use bonds to exercise option to receive shares of Vinhomes JSC (VHM VN/TRADING BUY/TP: VND112,000/CP: VND98,700) listed on HOSE. Source: VnExpress, Fiinpro, Bloomberg, Mirae Asset Research Mirae Asset Vietnam Research 2 March 24, 2021 Good Morning Vietnam Market events Upcoming market events Ex-rights date Exercise date Ticker Exchange Event type Wednesday, March 24, 2021 3/24/2021 TLH VN HOSE Annual General Meeting 3/24/2021 4/9/2021 TLH VN HOSE Cash dividend (VND500/share) 3/24/2021 SJS VN HOSE Annual General Meeting 3/24/2021 PGC VN HOSE Annual General Meeting 3/24/2021 HDG VN HOSE Annual General Meeting 3/24/2021 4/23/2021 SMC VN HOSE Annual General Meeting 3/24/2021 4/23/2021 HDB VN HOSE Annual General Meeting 3/24/2021 4/23/2021 BMI VN HOSE Annual General Meeting 3/24/2021 4/24/2021 NKG VN HOSE Annual General Meeting 3/24/2021 4/27/2021 D2D VN HOSE Annual General Meeting 3/24/2021 4/28/2021 NT2 VN HOSE Annual General Meeting Thursday, March 25, 2021 3/25/2021 NCT VN HOSE Annual General Meeting 3/25/2021 DCM VN HOSE Annual General Meeting 3/25/2021 CTR VN UPCOM Annual General Meeting 3/25/2021 AAA VN HOSE Annual General Meeting 3/25/2021 4/20/2021 DPM VN HOSE Annual General Meeting 3/25/2021 4/23/2021 TPB VN HOSE Annual General Meeting 3/25/2021 4/23/2021 TAC VN HOSE Annual General Meeting 3/25/2021 4/23/2021 PME VN HOSE Annual General Meeting 3/25/2021 4/25/2021 DBC VN HOSE Annual General Meeting 3/25/2021 4/26/2021 SCR VN HOSE Annual General Meeting 3/25/2021 4/26/2021 SAM VN HOSE Annual General Meeting 3/25/2021 4/26/2021 KDC VN HOSE Annual General Meeting 3/25/2021 4/27/2021 POW VN HOSE Annual General Meeting 3/25/2021 4/27/2021 PET VN HOSE Annual General Meeting 3/25/2021 4/27/2021 MBB VN HOSE Annual General Meeting 3/25/2021 4/28/2021 TID VN UPCOM Annual General Meeting 3/25/2021 4/28/2021 PVS VN HNX Annual General Meeting Friday, March 26, 2021 3/26/2021 TCB VN HOSE Annual General Meeting 3/26/2021 SGB VN UPCOM Annual General Meeting 3/26/2021 NHH VN HOSE Annual General Meeting 3/26/2021 EVG VN HOSE Annual General Meeting 3/26/2021 4/23/2021 ABS VN HOSE Annual General Meeting 3/26/2021 4/26/2021 BAB VN HNX Annual General Meeting 3/26/2021 4/27/2021 VNG VN HOSE Annual General Meeting 3/26/2021 4/27/2021 VCG VN HOSE Annual General Meeting 3/26/2021 4/27/2021 TTF VN HOSE Annual General Meeting 3/26/2021 4/27/2021 IJC VN HOSE Annual General Meeting 3/26/2021 4/27/2021 DP3 VN HNX Annual General Meeting 3/26/2021 6/28/2021 DP3 VN HNX Cash dividend (VND8,000/share) 3/26/2021 4/28/2021 SNZ VN UPCOM Annual General Meeting 3/26/2021 4/28/2021 SAB VN HOSE Annual General Meeting 3/26/2021 4/29/2021 TCD VN HOSE Annual General Meeting Source: Mirae Asset Research, FiinPro Mirae Asset Vietnam Research 3 March 24, 2021 Good Morning Vietnam Technical analysis Summary Item Data Item Views Close (23 March., 2021) 1,183.45 (-0.92%) Short-term Sideways Resistance 1,200 Medium-term Sideways Support 1,100 Long-term Upsides VN-INDEX TECHNICAL CHART Source: Fdata, Mirae Asset Research Mirae Asset Vietnam Research 4 March 24, 2021 Good Morning Vietnam Equity market indicators Figure 1.
Load more

Recommended publications
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]
  • Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data
    Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Matt Eberle, Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. Diane Webb, President and Co-Founder, BizInt Solutions, Inc. Wednesday, March 24, 2021, 2:00 pm ET This session will start momentarily…. Webinar Host Susie Corbett PHT Chair Pharmaceutical & Health Technology Community https://connect.sla.org/pht/home Matt Eberle Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. [email protected] Following over ten years of experience at Wyeth, Pfizer and Sunovion as a Senior Information Scientist and Pharmaceutical Information Analyst, since 2013 Matt has helped BizInt customers use the BizInt Smart Charts and VantagePoint tools to create new solutions to address their challenges and problems. Matt lives outside Boston, MA. Diane Webb President and Co-Founder, BizInt Solutions, Inc. [email protected] Diane has over 30 years of experience managing the development of software tools to analyze and present competitive intelligence information, with a focus on drug pipeline, clinical trial and patent data. In 1996 Diane and John Willmore started BizInt Solutions to develop and market the BizInt Smart Charts product family. Diane & John live near Seattle, WA, with their current pack of four longhaired dachshunds. Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Part I: Dashboard visualizations and initial challenges PHT Pharma
    [Show full text]
  • Impfstoffkandidaten Gegen SARS-Cov-2, Die Sich Aktuell In
    Impfstoffkandidaten gegen SARS-CoV-2, die sich aktuell in klinischer Prüfung befinden (Vereinfachte Übersicht, kein Anspruch auf Vollständigkeit, alle Angaben ohne Gewähr; Stand: 12.03.2021; die Reihenfolge der Darstellung wurde der Abbildung Strategien der SARS-CoV-2- Impfstoffentwicklung angeglichen sowie eine weitere Kategorie hinzugefügt; inhaltliche Änderungen im Vergleich zur Vorversion sind farblich gekennzeichnet) IMPFSTOFF-PLATTFORM/- ENTWICKLER KLINISCHE STUDIEN ART (HAUPTSITZ) (STUDIENORT)* VIRUSBASIERTE IMPFSTOFFE Inaktivierter Virusimpfstoff Wuhan Institute of Biological Phase 1/2 (China) (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Marokko) Phase 3 (Peru) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Beijing Institute of Biological Phase 1/2 (China) BBIBP-CorV (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Argentinien) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Sinovac Phase 1/2 (China) CoronaVac (China) Phase 1/2 (China) (SARS-CoV-2) Phase 1/2 (China) Phase 2 (Brasilien, immunsupprimierte Patienten) Phase 3 (Brasilien) Phase 3 (Indonesien) Phase 3 (Türkei) Phase 3 (China) Phase 3 (Chile) Phase 4 (Brasilien; Rekru- tierung noch nicht begonnen) Phase 4 (Brasilien) Phase 4 (Hong Kong, Patienten mit chron. Lebererkrankungen; Rekrutierung noch nicht begonnen) Inaktivierter Virusimpfstoff Institute of Medical Biology, Phase 1 (China) (SARS-CoV-2) Chinese Academy of Medical Phase 1/2 (China) Sciences (China) Nationale Lenkungsgruppe Impfen,
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 12 Agosto 2021
    Coronavirus: quello che c’è da sapere – 12 agosto 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................27 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................27 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................33 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................51 I bambini sono più soggetti all’infezione? .............................................15 Quali sono i rischi sanitari legati all’epidemia? .....................................64
    [Show full text]
  • Coronavirus Vaccine Tracker
    https://nyti.ms/2MHNdRL U.S.A. World Health Coronavirus Vaccine Tracker By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021 PHASE 1 PHASE 2 PHASE 3 AUTHORIZED APPROVED ABANDONED 50 35 23 5 8 4 Vaccines Vaccines Vaccines Vaccines Vaccines Vaccines testing safety in expanded in large-scale in early or approved abandoned and dosage safety trials efficacy tests limited use for full use after trials Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals. New additions and recent updates April 5 The Walter Reed Army Institute of Research enters Phase 1. April 5 Japanʼs KM Biologics begins Phase 1/2. April 2 Franceʼs OSE Immunotherapeutics enters Phase 1. March 31 The Pfizer-BioNTech vaccine is highly effective in adolescents. March 31 Some Johnson & Johnson doses are delayed by a U.S. factory mix-up. March 30 Chinaʼs Jiangsu Rec-Biotechnology enters Phase 1. March 27 Turkeyʼs Middle East Technical and Bilkent University begin Phase 1. March 25 A vaccine from Chinaʼs Zhongyianke Biotech enters Phase 2. March 23 U.S. officials question the completeness of AstraZenecaʼs trial results. March 23 Daiichi Sankyo and the University of Tokyo enter Phase 1/2. March 22 AstraZenecaʼs vaccine is found to be 79% effective in a large U.S.
    [Show full text]
  • Covid-19 Under Democracy and Autocracy
    © Rutgers, The State University of New Jersey (New Brunswick) This publication is the work of the Spring 2021 Capstone class of the United Nations and Global Policy Studies Master of Arts program (UNMA), Political Science Department, Rutgers University (New Brunswick) June 2021 Application for permission to reproduce or translate all or any part of this publication should be made to: UNMA Secretariat Hickman Hall 89 George Street New Brunswick, NJ 08901 Email: [email protected] Title: Covid-19 Under Democracy and Autocracy Editor: Dr. Roland Rich Cover Design: Ian DeFalco Layout: Camilla Bober ISBN 978-0-578-92527-1 CONTENTS Contributors 1 Chapter 1 A Project is Born 4 Roland Rich Chapter 2 Australia’s Covid-19 Response: 10 The Achilles Heel Shahinaz Abdelhamid Chapter 3 Brazil: Negligence and Populism during 34 a Global Health Crisis Gabriela Casco Chapter 4 Cuba’s Vaunted Medical System Faces Covid-19 54 Javier Nino Chapter 5 Federalism, the EU, and Human Rights 68 in Germany under COVID-19 Camilla Bober Chapter 6 Russia: A Contest between Science and Denial 94 Amar Wason Chapter 7 South Africa Faces Covid-19 116 Delaney Charydczak Chapter 8 Taiwan: A Near Perfect Response 128 to the Coronavirus Pandemic Ryan Prieto Chapter 9 The Impact of Covid-19 on Elections 148 in Uganda Susan Ombwayo Chapter 10 The United Kingdom: Covid-19 162 and the Decay of Democracy Arsanious Hanna Chapter 11 Vietnam: Looking beyond Regime Type 182 Daphnée A.M. Fleurant Chapter 12 Conclusions, Constatations and Concerns 196 Roland Rich Bibliography 224 1 CONTRIBUTORS Shahinaz Abdelhamid received her B.S.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • Vaccines and Vaccinations in Southeast Asia's Fight Against
    ISSUE: 2021 No. 58 ISSN 2335-6677 RESEARCHERS AT ISEAS – YUSOF ISHAK INSTITUTE ANALYSE CURRENT EVENTS Singapore | 29 April 2021 Vaccines and Vaccinations in Southeast Asia’s Fight against Covid-19 Kevin S.Y. Tan and Grace Lim* Southeast Asia has made some headway in its collective response towards Covid-19 for prevention and detection, and the next step for the region to take is to progress towards vaccine independence. In this picture, vials of the CoronaVac vaccine, developed by China's Sinovac firm, are displayed in Bangkok on February 24, 2021, as the first batch of vaccines to battle the Covid-19 coronavirus arrive in the country. Photo: Lillian SUWANRUMPHA, AFP. *Kevin S.Y. Tan is Visiting Senior Fellow at the ISEAS – Yusof Ishak Institute and Adjunct Faculty at the School of Global Studies, Thammasat University. Grace Lim is a final year economics and management major at the University of London. 1 ISSUE: 2021 No. 58 ISSN 2335-6677 EXECUTIVE SUMMARY • Vaccines are now a vital component for all countries to turn the tide in the Covid-19 pandemic. • Partly due to vaccine nationalism, questions and issues surround the reliable supply of vaccines to Southeast Asia and the eventual normalisation of travel. • Vaccine diplomacy by growing vaccine powers such as China help address supply gaps in Southeast Asia, but come at the cost of increased dependency. • Southeast Asian states, through the support of ASEAN, need to enable multilateral recognition of vaccinations to restore travel and to work towards vaccine independence to avoid potential geopolitical vulnerability. 2 ISSUE: 2021 No.
    [Show full text]
  • Reasons for Success and Lessons Learnt from Nanoscale Vaccines Against COVID-19
    comment Reasons for success and lessons learnt from nanoscale vaccines against COVID-19 Almost all currently used vaccines against COVID-19 consist of either non-viral or viral nanoparticles. Here we attempt to understand the reasons behind the success of such advanced nanoscale vaccine technologies compared with clinically established conventional vaccines, and the lessons to be learnt from this potentially transformative development in the adoption and acceptance of nanotechnology for medicine. Thomas Kisby, Açelya Yilmazer and Kostas Kostarelos he outbreak of a novel coronavirus vaccine technologies such as those almost all of the candidates falling within the (CoV) causing severe acute based on inactivated/attenuated virions nanoscale size range (Fig. 1). Trespiratory syndrome (SARS) was (entire virus particles) or on viral protein The current scale of administration initially identified in China in late 2019 and fragments, which have traditionally led and therefore exposure to non-viral or rapidly developed into a global pandemic the way in terms of clinical presence, viral nanoparticles constitutes an with devastating health and economic market share and regulatory approval, unprecedented phenomenon of historic consequences1. Driven by this, concerted have been clearly outplayed in both speed proportions and implications. The effort by hundreds of laboratories across and immunoprotective efficacy by highly immediate reaction, even by some members the world has led to the most rapid vaccine innovative technologies with no prior of the scientific community, has been to development in history, with clinical approved clinical use4. Even more remarkable acclaim nanoscience and nanomedicine trials of promising candidates completed is that most of these vaccine candidates rely as ‘saviours’ of humankind.
    [Show full text]